09/09/2010 - CLAIRYG®, a new 5% concentrated, ready-to-use liquid intravenous immunoglobulin, is being launched in France in September 2010. CLAIRYG® is indicated for the treatment of primitive and secondary immunodeficiency and certain autoimmune and systemic deficiencies.About CLAIRYG®
CLAIRYG® is an intravenous immunoglobulin produced through a purification process involving state-of-the-art technological innovations to ensure high levels of immunoglobulin G (IgG) purity and biological safety.
LFB Biomédicaments obtained marketing authorisation from AFSSAPS for CLAIRYG® in December 2009.
Manufacturing stages particularly include caprylic acid fractionation, combined with ion exchange chromatography, accounting for CLAIRYG®’s great IgG purity and its very low anti-A and anti-B hemagglutinin content. The functional wholeness and physiological distribution of IgG sub-classes of CLAIRYG® are maintained in a unique, proprietary excipient formulation...
[...]
...About LFB:
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Immunology, Intensive Care and Hemostasis. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities internationally and develop innovative therapies. In 2009, LFB invested €76 million in research & development, i.e. 20% of its €376 million turnover. LFB Group is chaired by Christian Béchon and employs 1,700 people... LFB's Press Release - communiqué de presse LFB -
